Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
367.76B
Market cap367.76B
Price-Earnings ratio
118.54
Price-Earnings ratio118.54
Dividend yield
2.29%
Dividend yield2.29%
Average volume
9.57M
Average volume9.57M
High today
$149.43
High today$149.43
Low today
$147.06
Low today$147.06
Open price
$147.11
Open price$147.11
Volume
4.15M
Volume4.15M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 367.76B, Merck(MRK) trades at $149.06. The stock has a price-to-earnings ratio of 118.54 and currently yields dividends of 2.29%.

On 2026-10-21, Merck(MRK) stock traded between a low of $147.06 and a high of $149.43. Shares are currently priced at $149.06, which is +1.4% above the low and -0.2% below the high.

Merck(MRK) shares are trading with a volume of 4.15M, against a daily average of 9.57M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

Barron's 2h
Why This Phrama Pro Likes Johnson & Johnson, Eli Lilly, and Merck - Barron's

...

Why This Phrama Pro Likes Johnson & Johnson, Eli Lilly, and Merck - Barron's
TipRanks 8h
Merck’s Keytruda plus Padcev approved by EC for treatment of MIBC

Merck (MRK) announced the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev, as neoadjuvant treatment and then co...

24/7 Wall St. 1d
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Investing Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2% Moderna shares are surging ahead of a closely wa...

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

Benzinga 1d
Merck Discontinues Bacterial Infection Drug in Europe

Merck & Co Inc. (NYSE:MRK) is permanently discontinuing its bacterial infection therapy Zinplava (bezlotoxumab) for commercial reasons. European Regulators Rev...

Merck Discontinues Bacterial Infection Drug in Europe
Simply Wall St 1d
Merck Commits $2.9 Billion To Pennsylvania Drug Research And Manufacturing

Merck (NYSE:MRK) plans to invest US$2.9b to expand research and manufacturing operations in Montgomery County, Pennsylvania. The multi year build out focuses o...

Merck Commits $2.9 Billion To Pennsylvania Drug Research And Manufacturing
Zacks 2d
Merck Stock Dips While Market Gains: Key Facts

Merck (MRK Quick QuoteMRK - Free Report) closed the most recent trading day at $143.63, moving -1.59% from the previous trading session. This change lagge...

Merck Stock Dips While Market Gains: Key Facts
The Wall Street Journal 2d
Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

The German life-sciences and chemicals group said drug divesiran is ready to enter late-stage clinical trials. ralph orlowski / Reuters Germany’s Merck MRK -1....

Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
TipRanks 2d
Merck price target lowered to $155 from $160 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Merck (MRK) to $155 from $160 and keeps a Buy rating on the shares. Heading into Q3 results, Merck has continue...

Simply Wall St 5d
How Investors Are Reacting To Merck Phase 3 Skin Cancer Data

Merck announced that Paul J. Diaz, a healthcare investor and former CEO of Myriad Genetics and Kindred Healthcare, joined its board in November 2026. At the sam...

How Investors Are Reacting To Merck Phase 3 Skin Cancer Data
24/7 Wall St. 5d
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Investing Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know Bristol Myers Squibb has raised its dividend for 17 straight y...

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.